News and Announcements
SUDA Granted Japanese Patent for its Sldenafil-Based Products
- Published March 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that the Japan Patent Office has issued SUDA’s first Japanese patent for its sildenafil-based products, SUD-003 and SUD-004. The patent is titled: Oral Spray Formulations and Methods for Administration of Sildenafil. A patent application directed to similar subject matter has also been approved in Russia.
KEY TAKEAWAYS:
- Similar patents have been granted in the USA, Australia, New Zealand and Singapore; patent applications are pending in other jurisdictions.
- These patents provide protection until 2032.
- Administration of sildenafil, being the active pharmaceutical ingredient in SUD-003 and SUD-004, via an oral spray for the treatment of sexual dysfunction induced by Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants and for the treatment of pulmonary arterial hypertension (PAH).
- The global Erectile Dysfunction (ED) drugs market was valued at over US$ 4.4 billion in 2014. It affects about 150 million men worldwide and about 50% of men aged 40-88 suffer from the disorder.
Mr Stephen J Carter, SUDA’s CEO and Managing Director, commented: “We are delighted to have been issued this patent in Japan and to have had it approved in Russia. It reinforces our proprietary position covering the oral spray delivery of sildenafil for erectile dysfunction and pulmonary arterial hypertension. If we consider all countries where this patent or similar patents have been granted, then we have patent protection for SUD-003 and SUD-004 covering approximately 60% of the world’s healthcare market. We are finalising our new-generation formulation of SUD-003 with enhanced bioavailability and onset of action in preclinical models. In 2017, we anticipate continuing and furthering our discussions with prospective pharmaceutical partners globally who have shown interest in licensing our novel oral spray treatment for erectile dysfunction.”
Company Updates
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Backed By Leading Investment Groups and Family Offices
